Genomic analyses demonstrating NF1 or CDKN2A loss, which are thought to occur early in disease progression, are also suggestive of a diagnosis of MPNST over other malignancies. The gene discussed is CDKN2A; the disease is malignant peripheral nerve sheath tumor.